Forge Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Forge Therapeutics Inc.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
Privately held Avidity’s platform creates antibody-oligonucleotide conjugate therapies, which build on RNAi approaches. Basilea/Forge collaboration seeks to create novel antibiotics using metalloenzyme chemistry.
Building on a leading position in anti-infectives research, Evotec aims to develop a new class of antibacterials based on cystobactamids, which are found in slime bacteria and have potent activity against serious bacterial pathogens.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.